Azar: Proposal To Let Plans Negotiate Part B Drug Prices Is Most Important Aspect Of Trump’s Drug-Price Plan

May 14, 2018
HHS Secretary Alex Azar said Monday (May 14) that HHS’ proposal to subject Part B drugs to price negotiations in Part D is the most important piece of the president’s plan to contain drug costs. CMS could move all Part B drugs into Part D, or it could test the proposal on just a few drugs, and drugs would be chosen for the demonstration based on either price or therapeutic substitutability. In the retail drug benefit Part D program, private...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.